Penetrium Bioscience

Penetrium Bioscience traces its roots to ADM Korea (formerly Hyundai ADM Bio), a clinical research organization (CRO) established in 2003.

After being acquired by Hyundai Bioscience in 2024, the company secured an exclusive license to the Penetrium drug-delivery platform for KRW9.1 billion, expanding from CRO services into new drug development, and changed its name to reflect this shift in March 2026.

Its business structure is dual-track, combining legacy CRO services such as clinical trial outsourcing and data management with a new drug pipeline built around the Penetrium platform.

Following the 2024 acquisition by Hyundai Bioscience, the company has focused on developing anti-cancer therapies based on the Penetrium platform while continuing to provide clinical trial design, operation and data-management services to pharmaceutical and biotech clients as a CRO.

The core pipeline asset Penetrium targets so-called pseudo-resistance, in which a physical barrier surrounding the tumor rather than genetic mutation in the cancer cells itself blocks drug penetration.

Domestically, the company has obtained Phase 1 approval in breast and lung cancer patients and has begun a prostate cancer trial with Seoul National University Hospital, while also pursuing an indication expansion into rheumatoid arthritis.

In the United States, the FDA approved a Phase 2a IND in September 2026 for a combination trial with standard-of-care therapy in advanced solid tumors, a strategy that skipped Phase 1 based on human safety data already accumulated from the same formulation's use as a COVID-19 treatment and in a Vietnam dengue Phase 2/3 trial.

Its client base remains legacy CRO-outsourcing pharma and biotech firms, and on the drug-development side, observers note the company has comparatively weaker fundraising capacity than well-capitalized large biotechs or big pharma.

Penetrium Bioscience's annual revenue declined for four consecutive years, from about KRW14.88 billion in 2022 to KRW13.79 billion in 2023, KRW9.74 billion in 2024, and KRW9.27 billion in 2025.

The operating loss widened sharply from KRW0.75 billion in 2022 to KRW3.46 billion in 2023 and KRW15.93 billion in 2024, before narrowing to less than half that level at KRW7.38 billion in 2025.

However, the net loss attributable to controlling shareholders widened from KRW0.06 billion in 2022 to KRW2.97 billion in 2023 and KRW20.10 billion in 2024, and remained in deficit at KRW14.83 billion in 2025.

Operating margin came in at -5.1% in 2022, -25.1% in 2023, -163.5% in 2024 and -79.5% in 2025, showing that declining sales and rising clinical costs squeezed margins simultaneously.

On a quarterly basis, net profit attributable to controlling shareholders in Q2 2025 was the only positive quarter at KRW1.81 billion, a swing interpreted as reflecting non-operating factors related to convertible bonds, before reversing to a net loss of KRW8.46 billion in Q3 2025.

From Q4 2025 through Q2 2026, net losses were KRW4.53 billion, KRW1.87 billion and KRW1.51 billion respectively, showing a gradual narrowing trend in loss size. Over the same period the operating loss held in a range of roughly KRW1.5-1.9 billion per quarter, indicating steady clinical-trial spending.

Operating cash flow, which had been a positive KRW0.90 billion in 2022, turned negative for three straight years at -KRW3.08 billion in 2023, -KRW14.29 billion in 2024 and -KRW4.47 billion in 2025, while the combined net loss over the most recent four quarters (Q3 2025 to Q2 2026) reached KRW16.36 billion, underscoring a structure in which revenue alone cannot cover clinical spending.

Korea's CRO market is growing modestly on the back of expanding outsourcing demand for drug development, but intensifying competition between large global CROs and smaller domestic players continues to pressure outsourcing fees.

Penetrium Bioscience's legacy CRO revenue, spanning laboratory-services and clinical-trial operations, has slipped slightly in its most recent results, reflecting this industry backdrop.

On the drug-development side, approaches targeting the tumor microenvironment are drawing attention as a way to address the limitations of existing immuno-oncology therapies.

The company has positioned combination strategies with targeted and immune-checkpoint therapies as its core approach, citing safety data accumulated from the same formulation's use as a COVID-19 treatment and in a Vietnam dengue Phase 2/3 trial as grounds for accelerating clinical development.

It has also engaged in scientific forums such as the American Association for Cancer Research (AACR) annual meeting to seek partnerships with global pharma companies.

Still, most of its drug pipeline remains at early Phase 1-2 stages with many hurdles remaining before commercialization, and some in the investment-banking community have voiced concern that CRO operations and drug development require fundamentally different capabilities and business structures.

Competitively, the company is smaller than large global CROs, and on the drug-development side observers note it has comparatively weaker fundraising capacity than well-capitalized large biotechs or big pharma.

Having received FDA approval in September 2026 for a Phase 2a IND for a Penetrium combination regimen in advanced solid tumors, the company plans to begin a US multicenter trial combining Penetrium with standard-of-care chemotherapy.

Around the same time it plans to hold the 'Penetrium Global Symposium 2026' at the Grand InterContinental Parnas in Seoul to unveil its global combination Phase 2 development strategy.

For rheumatoid arthritis, the company is targeting IND filings in Korea, the US and the UK in the second half of 2026, with plans to enroll 48 patients domestically and ramp up recruitment from the first quarter of 2027.

However, a KRW73.8 billion rights offering planned in April 2026 saw its final issue price cut from KRW8,690 to KRW3,085 amid the stock's decline, reducing proceeds by roughly 24%, which in turn cut the R&D budget allocation by 25.7% from KRW26.9 billion to KRW20.0 billion.

In detail, the budget for the US basket Phase 2 trial was reduced from KRW13.26 billion to KRW10.0 billion, the rheumatoid arthritis Phase 2 budget from KRW8.44 billion to KRW6.0 billion, and the domestic solid-tumor Phase 1 budget from KRW2.98 billion to KRW2.0 billion.

Major shareholder Hyundai Bioscience issued a KRW10 billion private convertible bond to fund its full subscription to its allotted shares in the offering.

If the clinical timeline proceeds as planned, data from the domestic solid-tumor Phase 1 and US Phase 2 trials should be disclosed sequentially, though the possibility that the reduced budget affects trial speed or scale cannot be ruled out.